For adults with fatty liver disease, eating all meals within an 8-hour window each day does not improve markers of liver scarring over 12 weeks compared to spreading the same meals throughout the day, even when total food intake is unchanged.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether 16:8 TRE consistently improves liver fibrosis surrogates or histology in MASLD across long-term trials, accounting for baseline fibrosis stage, weight loss magnitude, and adherence.
A systematic review and meta-analysis of all RCTs comparing 16:8 TRE versus isocaloric standard eating in adults with MASLD, including at least 15 studies with 1,200+ participants total, measuring FIB-4, NFS, APRI, and liver biopsy or elastography as primary outcomes over 48+ weeks.
Whether 16:8 TRE causes improvement in liver fibrosis surrogates over 48 weeks in MASLD patients with moderate fibrosis (FIB-4 1.3–2.67), independent of weight loss.
A multicenter, double-blind RCT of 250 adults with MASLD and moderate fibrosis (FIB-4 1.3–2.67), randomized to 16:8 TRE or matched-calorie standard eating for 48 weeks, with liver stiffness measurement by FibroScan and FIB-4 as primary endpoints, and weight change as a covariate.
Whether adults with MASLD who adopt 16:8 TRE over 5 years have slower fibrosis progression compared to those who follow standard eating.
A prospective cohort study following 600 adults with MASLD and baseline fibrosis (FIB-4 >1.3) for 5 years, stratified by adherence to 16:8 TRE (≥70% days), measuring annual FibroScan and FIB-4 changes, adjusting for weight loss, diabetes, and alcohol intake.
Whether individuals with MASLD who progressed to advanced fibrosis over 3 years were less likely to have practiced 16:8 TRE compared to those who remained stable.
A case-control study comparing 120 MASLD patients who progressed to advanced fibrosis (FIB-4 >3.25) over 3 years to 120 matched controls who remained stable, assessing prior adherence to 16:8 TRE via structured dietary recall and wearable data.
Whether adults with MASLD currently practicing 16:8 TRE have lower fibrosis surrogate scores than those not practicing it, in a representative population.
A cross-sectional survey of 1,500 adults with MASLD, measuring current TRE adherence and FIB-4 score via standardized calculation from routine labs, adjusting for age, BMI, diabetes, and ALT.